Literature DB >> 27427299

An idiopathic thrombocytopenic purpura with polyneuropathy.

Valeria Katchan1,2, Paula David3,2, Yehuda Shoenfeld4,5.   

Abstract

Concurrent association of idiopathic thrombocytopenic purpura (ITP) and peripheral neuropathy is a rare condition. There are only few case reports published concerning peripheral neuropathy with ITP. One of the etiopathogenetic mechanisms proposed is intraneural hemorrhage, but the pathogenesis is not fully understood. Autoimmune nature with common antibodies to the platelets and the nerve´s myelin sheath should also be considered. Here we describe a 47-year-old woman, with a family history of autoimmune diseases. She was diagnosed 2 years ago with ITP and later developed a chronic combined inflammatory demyelinating polyneuropathy. Treatment with high-dose steroids was initiated with a poor response. The patient showed a clear improvement in platelet count and in the peripheral neuropathy symptoms when treatment with intravenous immunoglobulin was administered. Common etiologic mechanism of the two diseases should be considered, both, because of the simultaneous time of development and a similar response to intravenous immunoglobulin treatment.

Entities:  

Keywords:  Autoantibodies; Autoimmunity; Idiopathic thrombotic purpura; Intravenous immunoglobulin; Peripheral neuropathy

Mesh:

Substances:

Year:  2017        PMID: 27427299     DOI: 10.1007/s12026-016-8828-4

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  39 in total

1.  HEMORRHAGES INTO PERIPHERAL NERVES IN ASSOCIATION WITH LEUKEMIA.

Authors:  A BRUN; V CAVINESS; P RUDNICK; H R TYLER
Journal:  J Neuropathol Exp Neurol       Date:  1964-10       Impact factor: 3.685

2.  How long is IVIg effective in multifocal motor neuropathy?

Authors:  F Terenghi; A Cappellari; A Bersano; M Carpo; S Barbieri; E Nobile-Orazio
Journal:  Neurology       Date:  2004-02-24       Impact factor: 9.910

3.  Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients.

Authors:  J-M Léger; K Viala; F Cancalon; T Maisonobe; B Gruwez; T Waegemans; P Bouche
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-01       Impact factor: 10.154

4.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

Review 5.  How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment.

Authors:  Waleed Ghanima; Bertrand Godeau; Douglas B Cines; James B Bussel
Journal:  Blood       Date:  2012-06-26       Impact factor: 22.113

6.  Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report.

Authors:  Patrizia Dacci; Nilo Riva; Marina Scarlato; Irmgard Andresen; Dirksteffen Schmidt; Giancarlo Comi; Raffaella Fazio
Journal:  Neurol Sci       Date:  2010-06-24       Impact factor: 3.307

7.  Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  J R Mendell; R J Barohn; M L Freimer; J T Kissel; W King; H N Nagaraja; R Rice; W W Campbell; P D Donofrio; C E Jackson; R A Lewis; M Shy; D M Simpson; G J Parry; M H Rivner; C A Thornton; M B Bromberg; R Tandan; Y Harati; M J Giuliani
Journal:  Neurology       Date:  2001-02-27       Impact factor: 9.910

Review 8.  Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  H S Patwa; V Chaudhry; H Katzberg; A D Rae-Grant; Y T So
Journal:  Neurology       Date:  2012-03-27       Impact factor: 9.910

9.  Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment.

Authors:  R M Van den Berg-Vos; H Franssen; J H J Wokke; L H Van den Berg
Journal:  Brain       Date:  2002-08       Impact factor: 13.501

10.  Oculomotor nerve palsy due to intraneural hemorrhage in idiopathic thrombocytopenic purpura: a case report.

Authors:  S Miyao; A Takano; J Teramoto; S Fujitake; Y Hashizume
Journal:  Eur Neurol       Date:  1993       Impact factor: 1.710

View more
  1 in total

Review 1.  SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.

Authors:  Marcella Prete; Elvira Favoino; Giacomo Catacchio; Vito Racanelli; Federico Perosa
Journal:  Int J Mol Sci       Date:  2020-05-10       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.